PROMISE: a real‑world clinical‑genomic database to address knowledge gaps in prostate cancer
The PROMISE consortium establishes a real‑world clinical‑genomic platform that can fill critical knowledge gaps in precision medicine for prostate cancer.
PROMISE is a real‑world clinical‑genomic database designed to address knowledge gaps in assessing the molecular diversity of prostate cancer. The goal is to collect de-identified clinical and genomic data linked to patient outcomes to improve understanding of advanced prostate cancer and precision oncology. The consortium incorporates a dedicated bioinformatics committee to standardize genomic data quality control, a biostatistics committee for statistical analysis, an executive committee to review research proposals, a diversity/inclusion committee to address racial disparities, and a patient advocacy committee to incorporate patient perspectives. PROMISE provides a powerful clinical‑genomic platform to interrogate and address data gaps that have arisen with increased genomic testing in the clinical management of prostate cancer.
By aggregating diverse clinical and genomic data, PROMISE enables researchers and clinicians to better understand molecular heterogeneity in prostate cancer, identify actionable biomarkers, and guide therapeutic decision‑making in real‑world settings, thereby bridging gaps that are not fully captured in clinical trials.
Evidence level: Állatkísérletes. Állatmodellben vizsgálták.
Related signals
- Apalutamide Treatment and Metastasis‑free Survival in Prostate Cancer
- The prostate cancer conundrum revisited: Treatment changes and prostate cancer mortality declines
- The contemporary management of prostate cancer
- Extracellular TROP2 Fragment Identified as a Potential Biomarker and Metastasis Driver
- Overall survival of prostate cancer patients treated with Lu‑177 PSMA 617 (Pluvicto®) in a multidisciplinary setting— a single center experience